BioTE pellet therapy has documented side effects related to hormone peaks, delivery limitations, and insertion risks. As of 2026, multiple lawsuits allege informed consent failures and dosing-related harm. For patients experiencing instability, alternatives like injections and transdermal therapy offer more control and adjustability.
Medically reviewed by Dr. Frangos, MD — board-certified physician with experience in hormone optimization.
Pellet therapy is often marketed as:
👉 “set it and forget it”
But what many patients discover later is:
👉 once it’s in, it cannot be adjusted
And that single limitation explains most of the side effects, complaints, and lawsuits.
What side effects are associated with BioTE pellets?
Pellet therapy delivers a fixed hormone dose under the skin.
That dose is released over 3–6 months—whether your body needs more, less, or something different.
1. Early hormone peak effects (weeks 1–4)
This is when levels are often highest.
Common symptoms:
-
- acne (jawline, back)
- irritability or anxiety
- fluid retention
- elevated hematocrit (blood thickening risk)
- elevated estradiol from testosterone conversion
👉 These are often caused by supraphysiologic hormone levels, not individual sensitivity.
2. Virilization risks in women
When testosterone levels exceed the physiologic range:
Possible effects:
-
- voice deepening (may become permanent)
- facial hair growth
- clitoral enlargement
- hair thinning or loss
👉 These risks increase with higher or repeated dosing cycles.
3. Late-cycle “crash” symptoms (weeks 10–16)
As the pellet dissolves, levels may drop below therapeutic range.
Common symptoms:
-
- fatigue
- low libido
- mood instability
- poor sleep
- return of menopausal symptoms
👉 This is often called a “pellet crash”—and it’s predictable.
4. Insertion-site complications
While less common, these are documented:
-
- pain and bruising
- infection
- pellet extrusion (pushing out through the skin)
- scarring from repeated insertions
FDA regulatory concern
In 2019, the FDA reported that BioTE failed to report over 4,000 adverse events following inspection findings.
You can review general regulatory guidance on adverse event reporting through the
👉 FDA Safety Reporting Information
What the BioTE lawsuits are about
As of 2026, lawsuits are ongoing (not yet class action).
They focus on several key allegations:
1. Informed consent issues
Patients claim they were not told:
- dosing cannot be reversed
- hormone peaks are expected—not rare
- pellets are not FDA-approved
2. Product liability claims
- pellet extrusion
- infection
- procedural complications
3. Dosing protocol concerns
Some cases allege:
👉 dosing methods consistently produce excessively high hormone levels
This is especially reported in:
👉 women receiving both estrogen + testosterone pellets
4. Adverse event reporting failures
Based on FDA findings, some claims involve:
👉 lack of transparency about known risks
Important clarification
These lawsuits:
👉 do NOT claim pellets should be banned
They focus on:
- specific outcomes
- specific providers
- specific consent practices
What the evidence says about pellet limitations
Pellet therapy is not FDA-approved.
It is compounded under 503A pharmacy regulations, meaning:
👉 it does not undergo pre-market FDA safety review
Key pharmacokinetic limitations
1. Early hormone peaks
-
- men: often 1000–1500 ng/dL
- women: frequently above physiologic range
2. Variable absorption
Affected by:
-
- body fat
- activity level
- skin temperature
- pellet composition
👉 Same dose ≠ same outcome across patients
3. No dose adjustment
This is the biggest limitation.
Unlike other therapies:
👉 you cannot change the dose mid-cycle
Who does well on pellet therapy?
Pellets can work well for:
✔ patients with stable absorption
✔ those prioritizing convenience
✔ patients without peak/trough symptoms
Who tends to struggle
Problems are more common when:
-
- dosing is based on symptoms only (no labs)
- follow-up labs are not done at 4–6 weeks
- peak levels are not monitored
- patients are not informed about trough symptoms
👉 Lack of monitoring—not just the method—is often the issue.
What alternatives offer instead
Other delivery methods provide flexibility.
| Method | Advantage | Adjustable |
|---|---|---|
| Weekly testosterone injection | Precise control | Yes |
| Testosterone gel | Steady levels | Yes |
| Estradiol patch | Well-studied | Yes |
| Estradiol gel/spray | Good alternative | Yes |
👉 Transdermal estradiol avoids the increased clot risk seen with oral estrogen
(as noted in the NAMS Position Statement)
Related:
👉 women’s HRT overview
👉 women’s injectable testosterone
How to transition away from pellets
Timing matters more than method.
If you’re early in the cycle (weeks 1–6):
👉 wait before switching
Starting too early can cause hormone stacking.
If you’re in the trough phase (weeks 10–16):
👉 ideal time to transition
Levels are low enough to begin a new protocol safely.
If unsure:
👉 get labs
A single test + symptom review gives your provider a clear roadmap.
What patients report after switching
Most patients who move to injections or gel report:
-
- more stable energy
- fewer mood swings
- better symptom control
👉 usually within 6–8 weeks after stabilization
Where Amazing Meds fits in
Amazing Meds helps patients:
-
- review pellet-related lab patterns
- identify peak and trough issues
- build transition plans
- switch to adjustable therapies
Because the goal isn’t to stop hormone therapy.
👉 It’s to improve how it works for you.
If you want help reviewing your current therapy:
FAQ
Are BioTE pellets FDA-approved?
No. Pellet hormone therapy is compounded and not FDA-approved.
What is a pellet crash?
A drop in hormone levels near the end of the cycle (weeks 10–16).
Can pellet side effects be permanent?
Some effects (like voice deepening) may become permanent with prolonged high levels.
Are BioTE lawsuits a class action?
No. Current cases are individual or multi-plaintiff filings.
Should I stop hormone therapy if I have side effects?
No. Switching delivery methods is usually the better approach.